Treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis

• Main Authors: Anna Dmoszynska, Ewa Wasik-Szczepanek, Adam Walter-Croneck, Joanna Manko, Magdalena Malek, Wojciech Legiec, Dariusz Jawniak, Marek Hus, Maria Cioch, Malgorzata Wach
• Format: Article
• Language: English
• Published: Via Medica 2011-07-01
• Series: Folia Histochemica et Cytobiologica
• Subjects: multiple myeloma; high dose chemotherapy; autologous peripheral blood stem cell transplantation
• Online Access: http://czasopisma.viamedica.pl/fhc/article/view/4120
• ISSN: 0239-8508; 1897-5631

Patients with multiple myeloma (MM) treated with conventional chemotherapy have an average survival of approximately three years. High dose chemotherapy followed by autologous stem cell transplantation (ASCT), first introduced in the mid-1980s, is now considered the standard therapy for almost all patients with multiple myeloma, because it prolongs overall survival and disease free survival. Between November 1997 and October 2006, 122 patients with MM (58 females, 64 males, median age 51.0 years [± 7.98] range: 30–66 years) were transplanted in the Department of Hematooncology and Bone Marrow Transplantation at the Medical University of Lublin: 47 patients were in complete remission or in unconfirmed complete remission, 66 patients were in partial remission, and nine had stable disease. Of these, there were 95 patients with IgG myeloma, 16 with IgA myeloma, one with IgG/IgA, one with IgM myeloma, five with non secretory type, two with solitary tumor and two with LCD myeloma. According to Durie-Salmon, 62 patients had stage III of the disease, 46 had stage II and four had stage I. Most patients (69/122) were transplanted after two or more cycles of chemotherapy, 48 patients were transplanted after one cycle of chemotherapy, one patient after surgery and rtg- -therapy and four patients had not been treated. In mobilisation procedure, the patients received a single infusion of cyclophosphamide (4–6 g/m<sup>2</sup>) or etoposide 1.6 g/m<sup>2</sup> followed by daily administration of G-CSF until the peripheral stem cells harvest. The number of median harvest sessions was 2.0 (± 0.89) (range: 1–5). An average of 7.09 (± 33.28) × 106 CD34<sup>+</sup> cells/kg were collected from each patient (range: 1.8–111.0 × 106/kg). Conditioning regimen consisted of high dose melphalan 60–210 mg/m<sup>2</sup> without TBI. An average of 3.04 (± 11.59) × 106 CD34+ cells/kg were transplanted to each patient. Fatal complications occured in four patients (treatment- -related mortality = 3.2%). In all patients there was regeneration of hematopoiesis. The median number of days for recovery to ANC > 0.5 × 10<sup>9</sup>/l was 13 (± 4.69) (range: 10–38) and platelets recovery to > 50 × 10<sup>9</sup>/l was 25 days (± 11.65) (range: 12–45). Median time of hospitalization was 22 days (± 7.14) (range: 14–50). Patients were evaluated on day 100 after transplantation: 74.9% achieved CR and nCR, 14.3% were in PR, 5.4% had SD and 5.4% had progressed. Median of OS was 45 months (± 30.67). OS at 3-years was 84% and at 7-years 59%. Median PFS was 25 months (± 26.13). PFS at 3-years was 68%, and at 7-years was 43%. At present (November 2009) 52 patients (42%) are still alive. High-dose chemotherapy followed by autologous stem cell transplantation is a valuable, well tolerated method of treatment for patients with MM that allows the achievement of long- -lasting survival. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 248–254)